Waseem Chauhan & Rahima Zennadi. (2023). Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease. MDPI AG.
Chicago Style (17th ed.) CitationWaseem Chauhan and Rahima Zennadi. Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease. MDPI AG, 2023.
MLA (9th ed.) CitationWaseem Chauhan and Rahima Zennadi. Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease. MDPI AG, 2023.
Warning: These citations may not always be 100% accurate.